Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ACFN,
Moving higher,at 8.55 now.Seems like huge potential if their product is successful.
The best thing is the downside has been around 8 dollars.
http://finviz.com/quote.ashx?t=acfn&ty=c&ta=1&p=d
200 million dollar potential from this utility alone ,if it works out?
http://ih.advfn.com/p.php?pid=nmona&article=54538928
"The order represents an almost $ 1 million first sale for this new product , and will be processed and shipped in the fourth quarter . Assuming successful integration , the ultimate potential product sales volume with this utility could , over time , approach over 100 , 000 units across their network ."
Manny
ACFN,
Moving higher.
200 million dollar potential from this utility alone ,if it works out?
http://ih.advfn.com/p.php?pid=nmona&article=54538928
"The order represents an almost $ 1 million first sale for this new product , and will be processed and shipped in the fourth quarter . Assuming successful integration , the ultimate potential product sales volume with this utility could , over time , approach over 100 , 000 units across their network ."
Manny
ACFN,
Seems like huge potential here.
GridSense, an Acorn Energy Company, Announces Sale of Over 500 Pole-top & Underground TransformerIQ™ Monitors to Major Cali...
SACRAMENTO, Calif., Oct. 16, 2012 /PRNewswire/ -- GridSense, an Acorn Energy (NASDAQ: ACFN) company that develops and markets advanced monitoring solutions for the electric power industry announced the sale of 500 TransformerIQ™ advanced monitoring units to a major California utility. The 500 TransformerIQ™ devices will be used to monitor and secure valuable data from overhead and underground transformers dispersed throughout the utility's residential distribution grid. The order represents an almost $1 million first sale for this new product, and will be processed and shipped in the fourth quarter. Assuming successful integration, the ultimate potential product sales volume with this utility could, over time, approach over 100,000 units across their network.
(Logo: http://photos.prnewswire.com/prnh/20120426/NY96114LOGO )
(Logo: http://photos.prnewswire.com/prnh/20120504/NY01341LOGO )
"This sale is an integral part of the ongoing relationship we are developing with this major California utility," said Lindon Shiao, Chief Executive of GridSense. "The general public often equates the controversial smart meter on their home with the term smart grid. In fact, sophisticated Distribution Automation (DA) devices like TransformerIQ™ strategically placed throughout the network are really what the grid needs to become smarter. These devices can yield large economic benefits, similar to those of energy efficiency programs, but without requiring 300 million Americans to change their daily habits."
Greentech Media recently released a report stating, "Because automation of distribution systems, substations, and transmission grids offers more rapid and greater return on investments than smart meter programs, we believe that the DA market represents the greatest opportunity to reap the benefits of the smart grid."
John Moore, CEO of Acorn Energy stated, "I am very excited about how Lindon has positioned GridSense and with the Big Brother alliances he has developed to break into this new market. This utility is known as an early adopter and integrator of novel smart grid technologies. We take great pride in our developing relationship with this marquee customer. The biggest surprise to economic forecasters is going to be the impact of digital energy technologies like TransformerIQ™. They allow progressive utilities to affordably and quickly change their grid from thirty day batch processing to real-time self healing networks. Digital energy technologies like TransformerIQ™ will enable utilities to affordably reduce outage times and improve the reliability of the grid. The US Department of Energy estimates the cost of grid inefficiencies to the US economy to be $180 Billion each year. There are over thirty million pole-top and underground transformers in the US alone that are targets for our solution."
Adds Mr. Shiao, "I expect an acceleration of adoption of the pole-top and underground TransformerIQ™ by other utilities once we launch the GridInSite™ software platform in the first quarter of 2013. GridInSite™ will provide unprecedented real-time situational awareness of critical assets like transformers and overhead lines to grid operators."
About GridSense Inc.
GridSense is a smart grid technology company dedicated to providing innovative, practical and cost effective monitoring solutions to the electric power industry. Utilizing in-depth industry knowledge and understanding of utility requirements, we provide technology and services that help the industry address the limitations of old and aging infrastructure. We apply experience and technical know-how with new insight and ideas to create intelligent, reliable and leading edge technologies that add value to our customers and shape the future of the modern electrical power system.
About Acorn Energy, Inc.
Acorn Energy, Inc., the digital energy company is a holding company focused on making energy better by providing digital solutions for energy infrastructure asset management. The four businesses in which we have controlling interests, improve the world's energy infrastructure by making it: more secure - providing security solutions for underwater energy infrastructure (DSIT); more reliable - providing condition-based monitoring to critical assets on the electric grid (GridSense, OmniMetrix) and more productive and efficient - increasing oil and gas production while lowering costs through use of permanent ultra-high sensitive seismic tools that allow for a more precise picture of reservoirs (US Seismic). For more information visit: http://www.acornenergy.com.
Safe Harbor Statement
This press release includes forward-looking statements, which are subject to risks and uncertainties. There is no assurance that Acorn Energy, Inc. or its operating companies will continue to grow their respective businesses, or that any of them will meet the expectations or execute the initiatives described or referred to above. A complete discussion of the risks and uncertainties which may affect Acorn Energy's business generally and the businesses of its subsidiaries is included in "Risk Factors" in its most recent Annual Report on Form 10-K and its most recent 10-Q as filed by Acorn Energy with the Securities and Exchange Commission.
Contact: Leonce Gaiter
Tel: 916.372.4945
Email: l.gaiter@gridsense.com
SOURCE Acorn Energy, Inc.
Copyright 2012 PR Newswire
ACFN,
Huge potential here.
GridSense, an Acorn Energy Company, Announces Sale of Over 500 Pole-top & Underground TransformerIQ™ Monitors to Major Cali...
Print
Alert
Acorn Energy, Inc. (MM) (NASDAQ:ACFN)
Intraday Stock Chart
Today : Tuesday 16 October 2012
Click Here for more Acorn Energy, Inc. (MM) Charts.
SACRAMENTO, Calif., Oct. 16, 2012 /PRNewswire/ -- GridSense, an Acorn Energy (NASDAQ: ACFN) company that develops and markets advanced monitoring solutions for the electric power industry announced the sale of 500 TransformerIQ™ advanced monitoring units to a major California utility. The 500 TransformerIQ™ devices will be used to monitor and secure valuable data from overhead and underground transformers dispersed throughout the utility's residential distribution grid. The order represents an almost $1 million first sale for this new product, and will be processed and shipped in the fourth quarter. Assuming successful integration, the ultimate potential product sales volume with this utility could, over time, approach over 100,000 units across their network.
(Logo: http://photos.prnewswire.com/prnh/20120426/NY96114LOGO )
(Logo: http://photos.prnewswire.com/prnh/20120504/NY01341LOGO )
"This sale is an integral part of the ongoing relationship we are developing with this major California utility," said Lindon Shiao, Chief Executive of GridSense. "The general public often equates the controversial smart meter on their home with the term smart grid. In fact, sophisticated Distribution Automation (DA) devices like TransformerIQ™ strategically placed throughout the network are really what the grid needs to become smarter. These devices can yield large economic benefits, similar to those of energy efficiency programs, but without requiring 300 million Americans to change their daily habits."
Greentech Media recently released a report stating, "Because automation of distribution systems, substations, and transmission grids offers more rapid and greater return on investments than smart meter programs, we believe that the DA market represents the greatest opportunity to reap the benefits of the smart grid."
John Moore, CEO of Acorn Energy stated, "I am very excited about how Lindon has positioned GridSense and with the Big Brother alliances he has developed to break into this new market. This utility is known as an early adopter and integrator of novel smart grid technologies. We take great pride in our developing relationship with this marquee customer. The biggest surprise to economic forecasters is going to be the impact of digital energy technologies like TransformerIQ™. They allow progressive utilities to affordably and quickly change their grid from thirty day batch processing to real-time self healing networks. Digital energy technologies like TransformerIQ™ will enable utilities to affordably reduce outage times and improve the reliability of the grid. The US Department of Energy estimates the cost of grid inefficiencies to the US economy to be $180 Billion each year. There are over thirty million pole-top and underground transformers in the US alone that are targets for our solution."
Adds Mr. Shiao, "I expect an acceleration of adoption of the pole-top and underground TransformerIQ™ by other utilities once we launch the GridInSite™ software platform in the first quarter of 2013. GridInSite™ will provide unprecedented real-time situational awareness of critical assets like transformers and overhead lines to grid operators."
About GridSense Inc.
GridSense is a smart grid technology company dedicated to providing innovative, practical and cost effective monitoring solutions to the electric power industry. Utilizing in-depth industry knowledge and understanding of utility requirements, we provide technology and services that help the industry address the limitations of old and aging infrastructure. We apply experience and technical know-how with new insight and ideas to create intelligent, reliable and leading edge technologies that add value to our customers and shape the future of the modern electrical power system.
About Acorn Energy, Inc.
Acorn Energy, Inc., the digital energy company is a holding company focused on making energy better by providing digital solutions for energy infrastructure asset management. The four businesses in which we have controlling interests, improve the world's energy infrastructure by making it: more secure - providing security solutions for underwater energy infrastructure (DSIT); more reliable - providing condition-based monitoring to critical assets on the electric grid (GridSense, OmniMetrix) and more productive and efficient - increasing oil and gas production while lowering costs through use of permanent ultra-high sensitive seismic tools that allow for a more precise picture of reservoirs (US Seismic). For more information visit: http://www.acornenergy.com.
Safe Harbor Statement
This press release includes forward-looking statements, which are subject to risks and uncertainties. There is no assurance that Acorn Energy, Inc. or its operating companies will continue to grow their respective businesses, or that any of them will meet the expectations or execute the initiatives described or referred to above. A complete discussion of the risks and uncertainties which may affect Acorn Energy's business generally and the businesses of its subsidiaries is included in "Risk Factors" in its most recent Annual Report on Form 10-K and its most recent 10-Q as filed by Acorn Energy with the Securities and Exchange Commission.
Contact: Leonce Gaiter
Tel: 916.372.4945
Email: l.gaiter@gridsense.com
SOURCE Acorn Energy, Inc.
Copyright 2012 PR Newswire
STSI,
Research Presented at Neuroscience 2012 Indicates Anatabine Supplementation is Potentially Helpful in Recovery from Traumatic Brain Injury /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:8pt; font-family:"Arial"; color:black; } Research Presented at Neuroscience 2012 Indicates Anatabine Supplementation is Potentially Helpful in Recovery from Traumatic Brain Injury
PR Newswire
GLEN ALLEN, Va., Oct. 15, 2012
GLEN ALLEN, Va., Oct. 15, 2012 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: STSI) through its wholly owned subsidiary, Rock Creek Pharmaceuticals Inc., reports that scientists from its research partner, the Roskamp Institute, presented new research yesterday and today indicating that supplementation with anatabine, the active ingredient in the Company's Anatabloc® dietary supplement, has the potential to alleviate the negative consequences of traumatic brain injury (TBI). These findings were presented during a press conference and also at a nanosymposium presentation at Neuroscience 2012, the 42nd annual meeting of the Society for Neuroscience, attended by more than 32,000 neuroscientists from around the world. Those scientists are gathering in New Orleans, Louisiana, this week to observe and participate in presentations relating to more than 16,000 new discoveries in science and health.
(Logo: http://photos.prnewswire.com/prnh/20120301/NE62741LOGO)
On Sunday morning, Dr. Fiona Crawford, Associate Director and Vice President of the Roskamp Institute, was one of four presenters participating in a press conference titled," 'Invisible' Wounds: From Soldiers to Citizens", which focused on traumatic brain injury research working to improve the lives of citizens and soldiers. In the press conference, Dr. Crawford described the Roskamp Institute's larger traumatic brain injury research program and the Institute's work investigating anatabine's effect in laboratory models of TBI.
On Monday morning, Dr. Scott Ferguson, also of the Roskamp Institute, presented these data in a presentation titled, "TBI-Induced Spatial Memory Loss is Averted by Treatment with the Dietary Supplement Anatabine". In this study, three groups of mice were studied: One group of TBI mice was treated with anatabine, while a second group of TBI mice was untreated. A third group was comprised of normal mice. The results of the study showed that the untreated TBI mice demonstrated memory impairment; whereas, the memory of anatabine treated TBI mice was the same as normal mice. The scientists at the Roskamp Institute hypothesize that the maintenance of normal memory in TBI mice treated with anatabine is due to an inhibition of inflammation. The presentation abstract notes: "Anatabine treatment appeared to completely prevent the loss of spatial memory retention following severe TBI."
Dr. Crawford stated, "Further study of this promising treatment is warranted and will include evaluation in a mild closed head injury model as well as assessment of long term outcome from injury." Dr. Michael Mullan, President and CEO of the Roskamp Institute, explained, "Dietary supplementation to prevent memory loss after head injury has a potentially rapid development path for human use." According to the Centers for Disease Control, 1.7 million people in the United States experience TBI each year, with 80,000 survivors suffering long-term disability.
In addition to the TBI research, the Roskamp Institute presented results of its research examining the potential benefit of anatabine for alleviating symptoms associated with Multiple Sclerosis and will present new research on anatabine's effect on Alzheimer's Disease at the conference. For more information about the TBI study and the MS study, visit the Roskamp Institute's website at: www.rfdn.org
Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials, the challenges inherent in new product development initiatives, including the continued development and market acceptance of our nutraceutical and low-TSNA tobacco products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, including with respect to our nutraceutical and low-TSNA tobacco products, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on Form 10-K for the fiscal year ended December 31, 2011. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.
About Star Scientific ?
Star Scientific, Inc. is a technology-oriented company with a mission to promote maintenance of a healthy metabolism, as well as to reduce the harm associated with the use of tobacco at every level. Over the last several years, through its wholly owned subsidiary, Rock Creek Pharmaceuticals, Star Scientific has been engaged in the manufacturing, sale, and marketing of two nutraceutical dietary supplements, and the development of other nutraceuticals and pharmaceuticals. The company also has continued to pursue the development, implementation, and licensing of the technology behind its proprietary StarCured® tobacco curing process, which substantially prevents the formation of carcinogenic toxins present in tobacco and tobacco smoke, primarily the tobacco-specific nitrosamines, or TSNAs and related low-TSNA dissolvable tobacco products. Rock Creek Pharmaceuticals has scientific and research offices in Gloucester, MA, and a regulatory office in Washington, DC. Star Scientific has a Corporate and Sales Office in Glen Allen, VA; Executive, Scientific & Regulatory Affairs offices in Bethesda, MD, and Washington, DC; and a manufacturing facility in Chase City, VA.
Contact: ?Talhia T. Tuck ?Vice President, Communications and Investor Relations ?Star Scientific, Inc. ?(202)887-5100 ttuck@starscientific.com
SOURCE Star Scientific, Inc.
CLSN,
Director Alberto Martinez exercises 37,002 shares mostly at 2.77,"with no immediate intent to sell"
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8510197
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Warrants to purchase Celsion Corporation Common Stock $ 2.77 10/15/2012 X 34,542 (1) 11/26/2011 05/26/2017 Celsion Corporation Common Stock 34,542 (1) $ 2.77 (1) 37,083 D
Warrants to purchase Celsion Corporation Common Stock $ 2.36 10/15/2012 X 2,500 (2) 12/06/2011 12/06/2016 Celsion Corporation Common Stock 2,500 (2) $ 2.36 (2) 34,583 D
Explanation of Responses:
1. The Director purchased Celsion Corporation Common Stock through the exercise of warrants obtained in the May 2011 PIPE Stock Offering. These warrants were fully exercisable with an exercise price of $2.77 per share. The Director has no immediate intent to sell these newly acquired shares.
2. The Director purchased Celsion Corporation Common Stock through the exercise of warrants obtained in the December 2011 PIPE Stock Offering. These warrants were fully exercisable with an exercise price of $2.36 per share. The Director has no immediate intent to sell these newly acquired shares.
CLSN,
Director Alberto Martinez exercises 37,002 shares mostly at 2.77,"with no immediate intent to sell"
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8510197
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Warrants to purchase Celsion Corporation Common Stock $ 2.77 10/15/2012 X 34,542 (1) 11/26/2011 05/26/2017 Celsion Corporation Common Stock 34,542 (1) $ 2.77 (1) 37,083 D
Warrants to purchase Celsion Corporation Common Stock $ 2.36 10/15/2012 X 2,500 (2) 12/06/2011 12/06/2016 Celsion Corporation Common Stock 2,500 (2) $ 2.36 (2) 34,583 D
Explanation of Responses:
1. The Director purchased Celsion Corporation Common Stock through the exercise of warrants obtained in the May 2011 PIPE Stock Offering. These warrants were fully exercisable with an exercise price of $2.77 per share. The Director has no immediate intent to sell these newly acquired shares.
2. The Director purchased Celsion Corporation Common Stock through the exercise of warrants obtained in the December 2011 PIPE Stock Offering. These warrants were fully exercisable with an exercise price of $2.36 per share. The Director has no immediate intent to sell these newly acquired shares.
CUR,
Significant Recovery Of Motor And Neurological Functions In Ischemic Stroke Rats With Neuralstem NSI-566 Cells
10/15 09:15 AM
ROCKVILLE, Md., Oct. 15, 2012 /PRNewswire/ -- Neuralstem, Inc. (CUR:$1.0997,$-0.0303,-2.68%) announced that data on Neuralstem (CUR:$1.0997,$-0.0303,-2.68%) 's NSI-566 spinal cord-derived neural stem cell line in a rat model of ischemic stroke was presented in a poster, "Histopathological Assessment of Adult Ischemic Rat Brains after 4 Weeks of Intracerebral Transplantation of NSI-566RSC Cell Line," at The Society for Neurosciences Annual Meeting (http://www.sfn.org/AM2012/). This study was conducted independently in the laboratory of Dr. Cesar Borlongan, who is the director at the Center of Excellence for Aging and Brain Repair at the University of South FloridaCollege of Medicine. Post-mortem histology was conducted in collaboration with Neuralstem. Rats that suffered ischemic stroke by middle cerebral artery occlusion, were transplanted 7 days post-stroke with increasing doses of NSI-566 into the stroke area. The animals were followed for safety and behavioral response for 56 days post-transplantation. Researchers reported Saturday that there was significant improvement in both motor and neurological tests in the stem cell-treated rats. There were significant dose-dependent differences in the behavioral improvement across treatment groups at post-transplantation periods, with the highest dose showing the most significant improvement in both motor and neurological tests. Similarly, there were significant differences in the behavioral performance among treatment groups at post-transplantation periods, with the most significant improvement in both motor and neurological tests seen at day 56 post-transplantation.
(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )
"This study was designed to evaluate the potential therapeutic value of intracerbral dosing of human neural stem cells (NSI-566, supplied by Neuralstem (CUR:$1.0997,$-0.0303,-2.68%) ) in an animal model of adult ischemic stroke," said Cesar V. Borlongan, Ph.D., University of South FloridaCollege of Medicine, and the lead study author. "The results are very clear. The recovery of motor and neurological tests demonstrated by high-dose transplanted stroke animals was significantly better throughout the 56-day study period compared to vehicle-infused stroke animals, or low-dosed animals. In addition, there was stable improvement in the high-dose animals, and they showed a trend of better improvement over time."
A separate poster, "Survival and Differentiation of Human Neural Stem Cells (NSI-566RSC) After Grafting into Ischemia-Injured Porcine Brain," was also presented on Saturday. This study was independently carried out by Dr. Martin Marsala and his colleagues. Dr. Marsala is a professor and the head of the Neuroregeneration Laboratory at University of California San Diego and also a member of the Sanford Consortium for Regenerative Medicine. In this study, the same stem cells were transplanted into the brains of pigs that received an ischemic stroke on one side of the brain. 8-9 weeks after the ischemic event, which models chronic stroke in humans, feasibility and safety of escalating cell doses and injections were assessed. Body temperature, behavior, muscle tone and coordination, sensory function, food consumption, defecation, and micturition were monitored at least twice daily for the first 7 days, and once weekly thereafter, until termination. Up to 12 million cells in 25 cell injection deposits via 5 cannula penetrations were shown to be safe, which closely mimics the intended clinical route and method of delivery in future human clinical trials. At 6 weeks post-transplantation, there were no complications from the cell transplantation method or the cells. All animals recovered and showed progressive improvement with no distinction. All treated animals showed effective engraftment and neuronal maturation with extensive axonal projections. These data support the application of NSI-566RSC cell line to be transplanted into a chronic stage of previously ischemia-injured brain for treatment of motor deficits resulting from stroke.
"Our study was designed to evaluate the potential value of Neuralstem (CUR:$1.0997,$-0.0303,-2.68%) 's cells in a chronic model of ischemic stroke and in a species that allowed for the use of human scale transplantation tools and dosing," said Martin Marsala, MD, at the University of California at San DiegoMedical School, and the lead study author of the porcine study. "We have demonstrated clearly that both the route of administration and the cells are safe and well tolerated and that the cells survived and differentiated into mature neurons in the host brain tissue."
"We have demonstrated safety and efficacy of NSI-566RSC in a subacute model of ischemic stroke in rats and feasibility and safety in a chronic model of ischemic stroke in mini-pigs," said Karl Johe, PhD, Chairman of Neuralstem (CUR:$1.0997,$-0.0303,-2.68%) 's Board of Directors and Chief Scientific Officer. "Together, these two studies demonstrate strong proof of principle data that our NSI-566 cells are ready to go into humans to treat paralysis in stroke patients."
Neuralstem (CUR:$1.0997,$-0.0303,-2.68%) has recently completed a Phase I trial testing the safety of NSI-566 in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and has been approved to initiate a human clinical trial in ischemic stroke in China, through its subsidiary, Suzhou Neuralstem.
CUR,
Significant Recovery Of Motor And Neurological Functions In Ischemic Stroke Rats With Neuralstem NSI-566 Cells
10/15 09:15 AM
ROCKVILLE, Md., Oct. 15, 2012 /PRNewswire/ -- Neuralstem, Inc. (CUR:$1.0997,$-0.0303,-2.68%) announced that data on Neuralstem (CUR:$1.0997,$-0.0303,-2.68%) 's NSI-566 spinal cord-derived neural stem cell line in a rat model of ischemic stroke was presented in a poster, "Histopathological Assessment of Adult Ischemic Rat Brains after 4 Weeks of Intracerebral Transplantation of NSI-566RSC Cell Line," at The Society for Neurosciences Annual Meeting (http://www.sfn.org/AM2012/). This study was conducted independently in the laboratory of Dr. Cesar Borlongan, who is the director at the Center of Excellence for Aging and Brain Repair at the University of South FloridaCollege of Medicine. Post-mortem histology was conducted in collaboration with Neuralstem. Rats that suffered ischemic stroke by middle cerebral artery occlusion, were transplanted 7 days post-stroke with increasing doses of NSI-566 into the stroke area. The animals were followed for safety and behavioral response for 56 days post-transplantation. Researchers reported Saturday that there was significant improvement in both motor and neurological tests in the stem cell-treated rats. There were significant dose-dependent differences in the behavioral improvement across treatment groups at post-transplantation periods, with the highest dose showing the most significant improvement in both motor and neurological tests. Similarly, there were significant differences in the behavioral performance among treatment groups at post-transplantation periods, with the most significant improvement in both motor and neurological tests seen at day 56 post-transplantation.
(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )
"This study was designed to evaluate the potential therapeutic value of intracerbral dosing of human neural stem cells (NSI-566, supplied by Neuralstem (CUR:$1.0997,$-0.0303,-2.68%) ) in an animal model of adult ischemic stroke," said Cesar V. Borlongan, Ph.D., University of South FloridaCollege of Medicine, and the lead study author. "The results are very clear. The recovery of motor and neurological tests demonstrated by high-dose transplanted stroke animals was significantly better throughout the 56-day study period compared to vehicle-infused stroke animals, or low-dosed animals. In addition, there was stable improvement in the high-dose animals, and they showed a trend of better improvement over time."
A separate poster, "Survival and Differentiation of Human Neural Stem Cells (NSI-566RSC) After Grafting into Ischemia-Injured Porcine Brain," was also presented on Saturday. This study was independently carried out by Dr. Martin Marsala and his colleagues. Dr. Marsala is a professor and the head of the Neuroregeneration Laboratory at University of California San Diego and also a member of the Sanford Consortium for Regenerative Medicine. In this study, the same stem cells were transplanted into the brains of pigs that received an ischemic stroke on one side of the brain. 8-9 weeks after the ischemic event, which models chronic stroke in humans, feasibility and safety of escalating cell doses and injections were assessed. Body temperature, behavior, muscle tone and coordination, sensory function, food consumption, defecation, and micturition were monitored at least twice daily for the first 7 days, and once weekly thereafter, until termination. Up to 12 million cells in 25 cell injection deposits via 5 cannula penetrations were shown to be safe, which closely mimics the intended clinical route and method of delivery in future human clinical trials. At 6 weeks post-transplantation, there were no complications from the cell transplantation method or the cells. All animals recovered and showed progressive improvement with no distinction. All treated animals showed effective engraftment and neuronal maturation with extensive axonal projections. These data support the application of NSI-566RSC cell line to be transplanted into a chronic stage of previously ischemia-injured brain for treatment of motor deficits resulting from stroke.
"Our study was designed to evaluate the potential value of Neuralstem (CUR:$1.0997,$-0.0303,-2.68%) 's cells in a chronic model of ischemic stroke and in a species that allowed for the use of human scale transplantation tools and dosing," said Martin Marsala, MD, at the University of California at San DiegoMedical School, and the lead study author of the porcine study. "We have demonstrated clearly that both the route of administration and the cells are safe and well tolerated and that the cells survived and differentiated into mature neurons in the host brain tissue."
"We have demonstrated safety and efficacy of NSI-566RSC in a subacute model of ischemic stroke in rats and feasibility and safety in a chronic model of ischemic stroke in mini-pigs," said Karl Johe, PhD, Chairman of Neuralstem (CUR:$1.0997,$-0.0303,-2.68%) 's Board of Directors and Chief Scientific Officer. "Together, these two studies demonstrate strong proof of principle data that our NSI-566 cells are ready to go into humans to treat paralysis in stroke patients."
Neuralstem (CUR:$1.0997,$-0.0303,-2.68%) has recently completed a Phase I trial testing the safety of NSI-566 in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and has been approved to initiate a human clinical trial in ischemic stroke in China, through its subsidiary, Suzhou Neuralstem.
SGMO,
SGMO-Sigma® Life Science Begins Licensing Efflux Transporter Knockout Human Cell-Based Assays to CROs and Pharmaceutical Companies Performing ADME Studies
Cyprotex is First to License Sigma's Exclusive Homozygous MDR1 (P-gp), BCRP and MRP2 Knockout Caco-2 Cell Lines for Identifying Drug-Transporter Interactions
ST. LOUIS, Oct. 15, 2012 /PRNewswire/ -- Sigma-Aldrich® Corporation (Nasdaq: SIAL) today announced that Sigma Life Science, its innovative biological products and services business, initiated a licensing program aimed at contract research organizations (CROs) and pharmaceutical companies for its novel CompoZr® Transporter Knockout Cell Lines for preclinical ADME screening and safety studies. Complete functional knockouts of transporters in the intestinal cell line (Caco-2) enables identification of critical safety and efficacy characteristics compared to current chemical inhibitor-based assays and more precise determination of a drug candidate's potential drug—drug interactions. Cyprotex, a leading ADME-Tox service company with sites in both the UK and USA, is the first non-exclusive licensee in the program. For more information, visit www.sigma.com/admetox.
The U.S. Food and Drug Administration and the European Medicines Agency recently recommended defining a drug candidate's interactions with efflux transporters, which act as doorways for drugs to exit or be expelled from human cells, to ascertain a drug candidate's probable safety profile and potential for adverse drug—drug interactions. Current efflux transporter assays use standard chemical inhibitors that can interact with multiple transporters simultaneously. This may produce an ambiguous representation of a drug candidates true ADME properties in the human body or potential contradictions with other medications.
"Complete transporter knockout human cell lines identify efflux transporter interactions unambigously to produce a clearly defined safety profile for a drug candidate. Sigma's CRO and pharma licensing program will facilitate rapid adoption of this superior approach to identifying potential safety issues and meeting the new regulatory guidelines," explains Paul Brooks, Ph.D., Market Segment Manager at Sigma Life Science.
The MDR1 (P-gp), BCRP and MRP2 Caco-2 single and double knockout cell lines were confirmed by genomic analysis and functional transporter activity assays. Sigma Life Science generated the cell lines using its CompoZr Zinc Finger Nuclease technology.
At the International Society for the Study of Xenobiotics' (ISSX) 18th North American Regional Meeting, new functional data on the gene knockout cell lines will be presented by Kathleen E. Sampson, Ph.D., Senior Scientist at Sigma Life Science, during an industry sponsored symposia on October 16 and a poster session on October 17, 2012.
For continuing ADME studies in animals, Sprague-Dawley rats containing identical homozygous efflux transporter gene knockouts are also available for purchase from Sigma Advanced Genetic Engineering (SAGE®) Labs.
For more information on the ISSX symposium, poster presentation or SAGE animal models, visit www.sigma.com/bioclarity.
http://investor.sigmaaldrich.com/releasedetail.cfm?ReleaseID=713263
SGMO,
Has been a good buy every time it breached the upward moving channel on the downside.
It is here again at 5.63 .
http://finviz.com/quote.ashx?t=sgmo&ty=c&ta=1&p=d
Hopefully it recovers again.
Manny
OT,
I have 2 windows for IV,and am having a hard time getting in.I keep switching to three url's,and same problem.
From IV:
|NOTE: If your IV pages are very slow to load, we are aware of the problem and are looking into it. We believe we have narrowed it down to an issue with a Content Delivery Network we use to handle some of our images and data. It may be a regional problem, but we're not sure yet. Updates to follow. Sorry for the inconvenience. - close this "
Manny
NAVB,
Registration of 300,000 is for selling shareholders,not the company.
Manny
NAVB,
Moving higher to 2.70,possibly on this report,foundon IV:
Ladenburg Thalmann - Pulling Forward Potential Lymphoseek Launch Date Based on Positive FDA Meeting. NDA Resubmission in Early November; Abbreviated Review Expected.
HIGHLIGHTS
On 10/10/12 - exactly one month after receiving a Complete Response Letter (CRL) from FDA for Lymphoseek – NAVB completed a positive Type A meeting with the agency to confirm the necessary steps for resubmission. Based on the update, we are pulling forward the potential launch of Lymphoseek from 2Q13 to early 1Q13. Specifically, following the FDA meeting NAVB now believes nearly all of the issues raised in the CRL have been addressed by its contract manufacturers and resubmission is likely by early November. Additionally, NAVB expects FDA review will be limited to cGMP issues raised in the CRL and will not require a reexamination of the full NDA package. The primary gating factor to potential approval, in our view, is likely to be scheduling facility inspections for both of NAVB’s contract manufacturers. Assuming the inspections do not identify any new issues, we believe the remaining administrative review can be completed in less than 1 month. As such, we forecast a total review time of 1 to 3 months for a base case of an early 2013 approval. In the best-case-scenario FDA approval by the end of 2012 is possible. We view the most recent FDA update as another important de-risking event and expect shares of NAVB to trade higher in the coming months as management ticks off a series of near term milestones toward FDA clearance of Lymphoseek. Separately, Phase III results for Lymphoseek in melanoma patients were published in Annals of Surgical Oncology. We expect the publication to help drive adoption, if Lymphoseek receives FDA clearance. Reiterate Buy rating and $7.50 PT.
What’s New? NAVB completed a Type A meeting with FDA to discuss the CRL and potential NDA resubmission for Lymphoseek. The update from NAVB suggests nearly all cGMP issues raised in the CRL have been addressed by its two contract manufacturers. The company plans to resubmit the NDA by early November. Additionally, NAVB expects the FDA review to be limited in scope and focus primarily on cGMP issues. The FDA meeting was completed exactly 1 month after NAVB received the CRL.
Pulling Forward Timeline 3-6 Months: Based on the recent update we now forecast launch of Lymphoseek in early 1Q13 versus our prior forecast of 2Q13. Our timeline assumes 1-3 months to schedule follow up site inspections and complete the review.
Balance Sheet Adequate to Fund Through Revised Launch Timeline: NAVB had $17M in cash as of 6/30/12, access to $15M in untapped capacity under an existing credit facility, and annualized cash burn rate of $20M. Based on our revised timeline we believe NAVB can fund operations through launch of Lymphoseek and to profitability without the need for additional equity-linked financing.
Publication of Phase III Melanoma Data To Help Drive Adoption: Results from 2 Phase III studies of Lymphoseek in patients with melanoma were published in Annals of Surgical Oncology. A total of 235 lymph nodes contained blue dye and were removed and examined by pathology. A total of 232 nodes (98.7%) with blue dye also had uptake of Lymphoseek (p<0.001). Lymphoseek detected 364 lymph nodes for a reverse concordance of 63.7%. Pathology identified 45 positive nodes in 34 patients. Lymphoseek identified all 34 patients with positive nodes while blue dye missed 4 patients.
For detailed information and disclosures, including risks pertaining to this specific recommendation, please see the full research report and refer to Appendix A – for important research disclosures.
Regards,
Kevin DeGeeter
Director, Equity Research Analyst
Ladenburg Thalmann & Co. Inc.
1.212.409.2027
Link to Full Report: http://www.mediafire.com/view/?jj62z2flji3zvej
NAVB,
Moving higher to 2.70,possibly on this report,found on IV:
Ladenburg Thalmann - Pulling Forward Potential Lymphoseek Launch Date Based on Positive FDA Meeting. NDA Resubmission in Early November; Abbreviated Review Expected.
HIGHLIGHTS
On 10/10/12 - exactly one month after receiving a Complete Response Letter (CRL) from FDA for Lymphoseek – NAVB completed a positive Type A meeting with the agency to confirm the necessary steps for resubmission. Based on the update, we are pulling forward the potential launch of Lymphoseek from 2Q13 to early 1Q13. Specifically, following the FDA meeting NAVB now believes nearly all of the issues raised in the CRL have been addressed by its contract manufacturers and resubmission is likely by early November. Additionally, NAVB expects FDA review will be limited to cGMP issues raised in the CRL and will not require a reexamination of the full NDA package. The primary gating factor to potential approval, in our view, is likely to be scheduling facility inspections for both of NAVB’s contract manufacturers. Assuming the inspections do not identify any new issues, we believe the remaining administrative review can be completed in less than 1 month. As such, we forecast a total review time of 1 to 3 months for a base case of an early 2013 approval. In the best-case-scenario FDA approval by the end of 2012 is possible. We view the most recent FDA update as another important de-risking event and expect shares of NAVB to trade higher in the coming months as management ticks off a series of near term milestones toward FDA clearance of Lymphoseek. Separately, Phase III results for Lymphoseek in melanoma patients were published in Annals of Surgical Oncology. We expect the publication to help drive adoption, if Lymphoseek receives FDA clearance. Reiterate Buy rating and $7.50 PT.
What’s New? NAVB completed a Type A meeting with FDA to discuss the CRL and potential NDA resubmission for Lymphoseek. The update from NAVB suggests nearly all cGMP issues raised in the CRL have been addressed by its two contract manufacturers. The company plans to resubmit the NDA by early November. Additionally, NAVB expects the FDA review to be limited in scope and focus primarily on cGMP issues. The FDA meeting was completed exactly 1 month after NAVB received the CRL.
Pulling Forward Timeline 3-6 Months: Based on the recent update we now forecast launch of Lymphoseek in early 1Q13 versus our prior forecast of 2Q13. Our timeline assumes 1-3 months to schedule follow up site inspections and complete the review.
Balance Sheet Adequate to Fund Through Revised Launch Timeline: NAVB had $17M in cash as of 6/30/12, access to $15M in untapped capacity under an existing credit facility, and annualized cash burn rate of $20M. Based on our revised timeline we believe NAVB can fund operations through launch of Lymphoseek and to profitability without the need for additional equity-linked financing.
Publication of Phase III Melanoma Data To Help Drive Adoption: Results from 2 Phase III studies of Lymphoseek in patients with melanoma were published in Annals of Surgical Oncology. A total of 235 lymph nodes contained blue dye and were removed and examined by pathology. A total of 232 nodes (98.7%) with blue dye also had uptake of Lymphoseek (p<0.001). Lymphoseek detected 364 lymph nodes for a reverse concordance of 63.7%. Pathology identified 45 positive nodes in 34 patients. Lymphoseek identified all 34 patients with positive nodes while blue dye missed 4 patients.
For detailed information and disclosures, including risks pertaining to this specific recommendation, please see the full research report and refer to Appendix A – for important research disclosures.
Regards,
Kevin DeGeeter
Director, Equity Research Analyst
Ladenburg Thalmann & Co. Inc.
1.212.409.2027
Link to Full Report: http://www.mediafire.com/view/?jj62z2flji3zvej
HEB,
75 million dollar share sale agreement:
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8502073
"We have entered into a sales agreement with the Maxim Group LLC (“Maxim”) relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus (the “Maxim Agreement”). In accordance with the terms of the Maxim Agreement, we may offer and sell up to an aggregate of up to $75.0 million of our common stock, $0.001 par value per share, from time to time through Maxim, acting as agent."
Manny
I was just told by Schwab,that since the stock is in a pension plan and run by am administrator,it is treated differently from a regular retirement account.
They claim they deducted 15% last time,which i must have missed.
I will check it.
Is this for real?
TIA,
Manny
It is interesting that Schwab took off 15% off my dividend in my retirement account,and didn't last time.
is it enough for me to tell them they are not supposed to deduct from a retirement account?
Thanks,
Manny
Star Scientific ( STSI ) Pops Higher , Rumors of Supreme Court Victory Star Scientific , Inc . ( NASDAQ : STSI ) is seeing upside on speculation supreme court win . Shares are up 12 %
Manny
CLSN,
Same director as yesterday,Max Link exercises another 70,360 shares at average 3.273.He now owns 366,385 shares.
His transactions are in the second section called "other transactions"
http://www.secform4.com/insider-trading/749647.htm
Manny
CLSN,
Same director as yesterday,Max Link exercises another 70,360 shares at average 3.273.He now owns 366,385 shares.
His transactions are in the second section called "other transactions"
http://www.secform4.com/insider-trading/749647.htm
Manny
NAVB,
SBIR Grant awarded
Navidea Awarded SBIR Grant from the NIH for Development of Radio-Immuno-Guided Surgery (RIGS) Agent Aimed at Detecting Metastatic Cancer
4:01p ET September 20, 2012 (Business Wire)
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced the receipt of a Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI), National Institutes of Health (NIH), to fund the development of the Company's radio-immuno-guided surgery monoclonal antibody targeting agent for use in detecting metastatic sites in colorectal cancer. The SBIR grant has the potential for grant money up to a total of $1.5M over three years if fully funded. The first-year Phase I funding of $315,000, which has already been approved, is expected to enable Navidea to complete preclinical bridging activities using a RIGS tumor-antigen-targeted monoclonal antibody and prepare a standardization clinical trial protocol. Second and third year (Phase II) funding of up to $1.2M is contingent upon meeting certain Phase I success criteria, including Institutional Review Board (IRB) approval of the clinical trial protocol.
"We are pleased that NIH/NCI has recognized the potential value for Navidea's RIGS agent to significantly benefit surgeons in effectively locating cancerous tissues during surgery and enabling their more thorough surgical removal for better patient outcomes. We appreciate NCI's support as we complete these important preclinical studies and prepare for re-initiation of human clinical trials," said Mark Pykett, V.M.D., Ph.D., President and CEO of Navidea. "The development of our RIGS monoclonal antibody agent represents another clinical advancement of Navidea's pipeline of innovative precision diagnostic products, including Lymphoseek(R) and NAV4694, which target devastating oncologic and neurologic diseases."
About the RIGS Monoclonal Antibody Targeting Agent
The RIGS targeting agent is an investigational, tumor-specific, radio-labeled monoclonal antibody. It may be used during surgery to identify cancerous tissue undetectable by traditional diagnostic and intraoperative techniques. The RIGS monoclonal antibody agent may enable more effective surgeries caused by metastasized colorectal cancers leading to improved patient survival.
Before surgery, a cancer patient is injected with the RIGS targeting agent which circulates throughout the patient's body and binds specifically to cancer cell antigens or receptors. Concentrations of the RIGS targeting agent within affected tissue are then detected using a gamma probe and direct the surgeon to targeted tissue for removal.
About Colorectal Cancer and Metastatic Disease
With nearly 140,000 new diagnoses and 50,000 deaths each year in the U.S., adenocarcinomas of the colon and rectum are a common and deadly form of cancer. When patients are first diagnosed with these diseases, they undergo surgeries to remove their tumors. Colon and rectal (colorectal) cancers, like nearly all forms of cancer, are insidious in that they can spread or metastasize from their primary sites of origin to multiple locations throughout the body. Patients who eventually succumb to colorectal cancer are killed by the uncontrolled growth of these metastatic tumors. It is well established that for colorectal cancers the most common site to which the cancer will spread first is the liver. Frequently, it is still possible to cure or dramatically extend the life of a patient with liver metastases using surgery if their cancer has not yet spread beyond the liver. About one third of colorectal cancer patients undergo surgeries to remove liver metastases.
About Navidea Biopharmaceuticals, Inc.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing four radiopharmaceutical agent platforms - Lymphoseek(R), NAV4694, CFT and RIGScan(TM) - to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company's pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.
The Private Securities Litigation Reform Act of 1995 (the Act) provides a safe harbor for forward-looking statements made by or on behalf of the Company. Statements in this news release, which relate to other than strictly historical facts, such as statements about the Company's plans and strategies, expectations for future financial performance, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for the Company's products are forward-looking statements within the meaning of the Act. The words "believe," "expect," "anticipate," "estimate," "project," and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company's continuing operating losses, uncertainty of market acceptance of its products, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed in the Company's most recent Annual Report on Form 10-K and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.
SOURCE: Navidea Biopharmaceuticals, Inc.
Navidea Biopharmaceuticals, Inc.
Brent Larson, 614-822-2330
Sr. VP & CFO
CLSN,
Director exercises 35,000 shares at 2.72.He now owns 296,025 shares.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8477842
Manny
CLSN,
Director exercises 35,000 shares at 2.72.He now owns 296,025 shares.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8477842
Manny
I don't think you will see .49,because Insiders are buying higher.
Director Cohen bought 10,000 shares yesterday at .79.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8476957
Manny
ZGNX-Up 12.3% to 2.74.
Volume of 2,735,525,is 3 1/2 times the 10 day average volume of 809,800.
Manny
DVAX,
Is over 5 after hours,after closing at 4.53.
looks like the VP of Finance & PAO is missing out.
She exercised today 18,750 shares at .54,and sold at 4.53.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8471227
No news yet.
CEO buys 5,000 shares at 5.034 average..
http://www.secform4.com/insider-trading/749647.htm
Manny
CLSN,
CEO buys 5,000 shares at 5.034 average..
http://www.secform4.com/insider-trading/749647.htm
Manny
NAVB,
Nice to see the Chief Business Officer being confident,and putting over 40,000 dollars in the business at this price.
Shows confidence in the future.
Manny
NAVB,
Nice to see the Chief Business Officer being confident,and putting over 40,000 dollars in the business at this price.
Shows confidence in the future.
Manny
NAVB,
Added some at 2.71 on 2 more buys.Chief Business Officer added 15,000 today at 2.70.
http://www.secform4.com/insider-trading/810509.htm
Manny
NAVB,
Added some at 2.71 on 2 more buys.Chief Business Officer added 15,000 today at 2.70.
http://www.secform4.com/insider-trading/810509.htm
Manny
CUR has just traded 7 million shares,the number of shares in the offering,after only 1 1/2 hours.
This shows the tremendous demand for shares.The company could have canceled the offering and gotten a much better price the way the stock traded yesterday,and especially today.
Manny
Correction.
55 million shares at 1.20 is market Cap of 66 million.
Manny
Company is selling 1 million shares.Already 4.4 million shares traded,way above 1 dollar offering,now at 1.25,so there is huge demand.
Manny
CUR,
Prices 7 million shares at 1 dollar per share.
Manny
NAVB,
This Director bought 5,000 shares at 3.579 before the CRL,and 5,000 at 2.637 yesterday.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8469201
Manny
NAVB,
This Director bought 5,000 shares at 3.579 before the CRL,and 5,000 at 2.637 yesterday.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8469201
Manny
It is this "spit in your face" criminality by the powerful who disregard laws, that will keep Obama in office.
The average voter will say,I am suffering,let the rich suffer also.
Manny